Alx Oncology Holdings (ALXO) Amortization of Deferred Charges (2020 - 2026)
Alx Oncology Holdings (ALXO) reported Amortization of Deferred Charges of $68000.0 for Q1 2026, up 1.49% on a YoY basis from $67000.0 in Q1 2025, and down 5.56% sequentially from $72000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 5 years of Amortization of Deferred Charges data on file, last reported at $68000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 1.49% year-over-year to $68000.0; the trailing twelve-month figure through Mar 2026 stood at $281000.0 (up 4.85% YoY), and the FY2025 full-year result was $280000.0, up 5.66% from the prior year.
- Amortization of Deferred Charges retreated to $68000.0 in Q1 2026, from $72000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $72000.0 in Q3 2025 to a low of $61000.0 in Q1 2023.
- A 4-year average of $66384.6 and a median of $66000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges gained 9.09% in 2025 and rose 1.49% in 2026, its largest moves.
- Tracing ALXO's Amortization of Deferred Charges over 4 years: stood at $64000.0 in 2023, then increased by 7.81% to $69000.0 in 2024, then rose by 4.35% to $72000.0 in 2025, then retreated by 5.56% to $68000.0 in 2026.
- Business Quant data shows ALXO's Amortization of Deferred Charges at $68000.0 in Q1 2026, $72000.0 in Q4 2025, and $72000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 215.94 Mn | 215.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |